載入中
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
前收盤價
US$71.38
+US$6.365 · +9.79%
盤中時間採用ET。市場資料可能有所延遲。
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
日內區間
目前US$71.38
52週區間
目前US$71.38
盤中時間採用ET。市場資料可能有所延遲。
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
日內區間
目前US$71.38
52週區間
目前US$71.38
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 7.94億 USD | 4.77億 USD | 3.32億 USD | 1.69億 USD | 7841.1萬 USD |
| 銷售、一般及管理費用 | 1.29億 USD | 9290.2萬 USD | 6070萬 USD | 3981萬 USD | 2525.9萬 USD |
| 營業費用 | 9.24億 USD | 5.7億 USD | 4.68億 USD | 2.32億 USD | 1.04億 USD |
| 利息收入 | 1.2億 USD | 1.1億 USD | 6290.7萬 USD | 835.6萬 USD | 34.4萬 USD |
| 利息支出 | — | — | — | 2000 USD | 7000 USD |
| 折舊和攤銷 | 2486萬 USD | 1584.5萬 USD | 1017.1萬 USD | 945.3萬 USD | 345.7萬 USD |
| 營業利益 | −9.24億 USD | −5.7億 USD | −4.68億 USD | −2.32億 USD | −1.04億 USD |
| 淨利 | −7.67億 USD | −4.64億 USD | −4.02億 USD | −2.23億 USD | −1億 USD |
公司資料更新於 2026年10月11日。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$123.5
上漲空間 73.02%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2.79億0.01%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM2.26億0.29%787.4億 USD0.19%US$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB2.02億0.11%1853億 USD0.03%US$289.48+0.64%
State Street SPDR S&P Biotech ETFXBI1.31億1.33%98.74億 USD0.35%US$153.77+3.00%
Vanguard Morningstar Small-Cap Growth ETFVBK1.16億0.25%447億 USD0.05%US$344.74+1.22%
Vanguard Extended Market ETFVXF9279.29萬0.10%954億 USD0.05%US$235+0.80%
T. Rowe Capital Appreciation Equity ETFTCAF7622.66萬0.84%91.1億 USD0.31%US$43.59+0.90%
iShares Biotechnology ETFIBB7326.04萬0.70%108.2億 USD0.44%US$206.49+3.00%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFT. Rowe Capital Appreciation Equity ETFTCAFiShares Biotechnology ETFIBBAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
